SubHero Banner

Avastin® (bevacizumab) – Expanded indication

June 13, 2018 - Genentech announced the FDA approval of Avastin (bevacizumab), in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.

Download PDF